Concerned About the CPSO Draft Policy Titled “Continuity of Care?”
The following link will take you to the members’ only section of our website. Here you will find instructions on how to share your concerns about the CPSO draft policy. You will be […]
New Infliximab Biosimilar (Renflexis) Approved by ODB With LU code Criteria
To review the update from the MOHLTC, please visit this link: Renflexis FAQs. The updated ORA EAP Forms are available via this link: ORA EAP Forms. […]
OHIP+ Changes
With the recent change in provincial government leadership, many of you may be wondering how the OHIP+ Program will be affected. The ORA Executive has reached out to our key contacts at the […]
Updated: ORA Position – Biosimilar Non-Medical Switching
The ORA Board of Directors is pleased to publish an official position statement on non-medical switching. Recently, we amended the document to include Frequently Asked Questions. To review this important document, please visit […]
Announcing Call for 2018 Arthritis Alliance of Canada Research Awards Applications
The Arthritis Alliance of Canada (AAC) is pleased to launch the 3rd round of the Research Awards Program and announce the 2018 “Call for Applications”. The program was intended to nationally recognise high […]
Sad news on the passing of Dr. Sydney Gershon
We are sad to share the news that Dr. Sydney Gershon passed away on April 30, 2018 at Sunnybrook Hospital in Toronto. Dr. Gershon was a member of the Ontario Rheumatology Association, a […]
OMA & ORA Updates from Dr. Baer & Dr. Averns – Video Link
Please find below a link to access the archived video of the 2018 OMA update presented by Dr. Philip Baer, and the 2018 ORA update presented by Dr. Henry Averns on April 12, […]
Canadian Arthritis Patient Alliance (CAPA)
The Canadian Arthritis Patient Alliance (CAPA) has published a user-friendly and informative MTX resource. The document may be reviewed via this link: CAPA MTX Link […]
Changes to the Ontario Drug Benefit (ODB) Formulary effective February 28, 2018
New Single Source Drugs Metoject Subcutaneous (methotrexate sodium) 17.5mg/0.35mL, 20mg/0.4mL, 22.5mg/0.45mL, 25mg/0.5mL Inj Sol – Pref Syr (MDX) Changes to Limited Use (LU) Criteria Aclasta (zoledronic acid) (NOV) and Generics (DRR, TAR, […]
Ontario Drug Benefit Formulary
(Received from the Ministry January 24, 2018) We are pleased to provide you with the Summary of Changes – January 2018 to Edition No. 43 of the Ontario Drug Benefit (ODB) Formulary / […]
